These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 29720474)
1. Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer. Johnstone CN; Pattison AD; Gorringe KL; Harrison PF; Powell DR; Lock P; Baloyan D; Ernst M; Stewart AG; Beilharz TH; Anderson RL Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29720474 [TBL] [Abstract][Full Text] [Related]
2. FGF13 promotes metastasis of triple-negative breast cancer. Johnstone CN; Pattison AD; Harrison PF; Powell DR; Lock P; Ernst M; Anderson RL; Beilharz TH Int J Cancer; 2020 Jul; 147(1):230-243. PubMed ID: 31957002 [TBL] [Abstract][Full Text] [Related]
3. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer. Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117 [TBL] [Abstract][Full Text] [Related]
4. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer. Ring A; Kaur P; Lang JE BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919 [TBL] [Abstract][Full Text] [Related]
5. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model. Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975 [TBL] [Abstract][Full Text] [Related]
6. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766 [TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells. Schech A; Kazi A; Yu S; Shah P; Sabnis G Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781 [TBL] [Abstract][Full Text] [Related]
8. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497 [TBL] [Abstract][Full Text] [Related]
9. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095 [TBL] [Abstract][Full Text] [Related]
10. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265 [TBL] [Abstract][Full Text] [Related]
11. Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer. Kong B; Lv ZD; Wang Y; Jin LY; Ding L; Yang ZC Int J Clin Exp Pathol; 2015; 8(9):11076-83. PubMed ID: 26617826 [TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers. Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754 [TBL] [Abstract][Full Text] [Related]
13. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A. Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815 [TBL] [Abstract][Full Text] [Related]
15. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]
16. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers. Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988 [TBL] [Abstract][Full Text] [Related]
17. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling. Vishnoi M; Liu NH; Yin W; Boral D; Scamardo A; Hong D; Marchetti D Mol Oncol; 2019 Sep; 13(9):1913-1926. PubMed ID: 31216110 [TBL] [Abstract][Full Text] [Related]
18. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis. Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823 [TBL] [Abstract][Full Text] [Related]
19. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628 [TBL] [Abstract][Full Text] [Related]
20. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]